EVOX THERAPEUTICS
LIVE

Serial Number

79359336

Owner

Evox Therapeutics Limited

Attorney

LAURA POPP ROSENBERG

Filing Date

Dec 1, 2022

Add to watchlist:

No watchlists yet
View on USPTO

EVOX THERAPEUTICS Trademark

Serial Number: 79359336

EVOX THERAPEUTICS is a trademark filed by Evox Therapeutics Limited on December 1, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Evox Therapeutics Limited (10 trademarks)

Oxford Science Park, Medawar Centre,

Entity Type: 99

Trademark Details

Filing Date

December 1, 2022

Registration Date

Not Registered

Published for Opposition

January 21, 2025

Goods & Services

Scientific, medical and pharmaceutical research and development services; pharmaceutical drug development services; research and development of pharmaceutical preparations; scientific research and analysis services in the field of pharmaceuticals; biological research; clinical research in the field of transformational therapeutics; providing medical research and scientific research information in the field of filtration of exosomes from blood; scientific investigations for medical purposes; scientific laboratory services; medical research laboratory services; laboratory research services relating to pharmaceuticals; research and development in the field of biotherapeutics for the treatment of infectious diseases and metabolic disorders; consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; all of the foregoing excluding such services in the fields of digestive diseases, gastrointestinal diseases, constipation, gut health, weight loss, appetite suppressants, dietetic preparations, nutrition, and enzymes

Pharmaceuticals, namely, drug delivery agents in the form of exosomes consisting of compounds that facilitate the delivery of a wide range of pharmaceutical preparations; pharmaceutical preparations, namely, drug delivery agents in the form of exosomes that facilitate the delivery of pharmaceutical preparations; pharmaceutical preparations, namely, a drug delivery system comprising genetically engineered or purified exosomes for therapeutic use, namely, for the release of a wide variety of therapeutic agents; pharmaceutical preparations, namely, engineered exosomes to deliver pharmaceutical preparations in the nature of protein for genetic therapy; medicine, namely, drug delivery agents in the form of exosomes that facilitate the delivery of pharmaceutical preparations; medical preparations, namely, drug delivery agents in the form of exosomes that facilitate the delivery of pharmaceutical preparations; biological preparations for medical purposes, namely, for the treatment of cancer, diabetes, metabolic syndrome, dementia, and aging associated pathologies in the nature of mitochondrial disease, joint and ligament strains and tears, muscle atrophy, and muscular dystrophy; biological preparations for the treatment of cancer, diabetes, metabolic syndrome, dementia, and aging associated pathologies in the nature of mitochondrial disease, joint and ligament strains and tears, muscle atrophy, muscular dystrophy; biological preparations comprising exosomes, namely, drug delivery agents in the form of exosomes that facilitate the delivery of pharmaceutical preparations, for the treatment of cancer, diabetes, metabolic syndrome, dementia, and aging associated pathologies in the nature of mitochondrial disease, joint and ligament strains and tears, muscle atrophy, and muscular dystrophy; biological preparations comprising a therapeutic target protein-loaded exosome that facilitates the delivery of pharmaceutical preparations, for the treatment of cancer, diabetes, metabolic syndrome, dementia, and aging associated pathologies in the nature of mitochondrial disease, joint and ligament strains and tears, muscle atrophy, and muscular dystrophy; biological preparations comprising exosomes for pharmaceutical purposes that facilitate the delivery of pharmaceutical preparations, for the treatment of cancer, diabetes, metabolic syndrome, dementia, and aging associated pathologies in the nature of mitochondrial disease, joint and ligament strains and tears, muscle atrophy, and muscular dystrophy; biological reagents for medical use, namely, drug delivery agents in the form of exosomes that facilitate the delivery of pharmaceutical preparations; mixed biological preparations for medical purposes, namely, for the prevention and treatment of infectious diseases; mixed biological preparations for the prevention and treatment of infectious diseases; diagnostic reagents used in the fields of biological, genetic engineering and pharmaceutical research; diagnostic reagents comprising exosome used in the fields of biological, genetic engineering and pharmaceutical research; pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars and therapeutics, namely, extracellular vesicle (EV)-based nucleic acid therapeutics for the prevention and treatment of infections or infectious diseases; diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection; diagnostic kits comprised of medical diagnostic reagents and assays for testing of exosomes for use in disease detection; diagnostic kits comprised of medical diagnostic reagents and assays that test for the presence of cancer, diabetes, metabolic syndrome, dementia, and aging associated pathologies, namely, mitochondrial disease, joint and ligament strains and tears, muscle atrophy, and muscular dystrophy; all of the foregoing excluding such goods in the fields of digestive diseases, gastrointestinal diseases, constipation, gut health, weight loss, appetite suppressants, dietetic preparations, nutrition, and enzymes

Filing History

REFUSAL PROCESSED BY IB
Jun 21, 2025 RFNP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
May 21, 2025 ETOP
OPPOSITION INSTITUTED NO. 999999
May 21, 2025 OP.I
OPPOSITION NOTICE (IB REFUSAL) SENT TO IB
May 20, 2025 OPNS
OPPOSITION NOTICE (IB REFUSAL) CREATED
May 20, 2025 OPNC
EXTENSION OF TIME TO OPPOSE RECEIVED
Jan 30, 2025 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 21, 2025 NPUB
PUBLISHED FOR OPPOSITION
Jan 21, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 15, 2025 NONP
EXPARTE APPEAL TERMINATED
Dec 26, 2024 EXPT
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 23, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 23, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 23, 2024 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Dec 20, 2024 ERFR
EX PARTE APPEAL-INSTITUTED
Dec 20, 2024 EXPI
JURISDICTION RESTORED TO EXAMINING ATTORNEY
Dec 20, 2024 JURT
EXPARTE APPEAL RECEIVED AT TTAB
Dec 20, 2024 EXAF
CHANGE OF NAME/ADDRESS REC'D FROM IB
Nov 25, 2024 ADCH
NOTIFICATION OF FINAL REFUSAL EMAILED
Jun 20, 2024 GNFN
FINAL REFUSAL E-MAILED
Jun 20, 2024 GNFR
FINAL REFUSAL WRITTEN
Jun 20, 2024 CNFR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Jun 7, 2024 OPNR
ASSIGNED TO EXAMINER
May 14, 2024 DOCK
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 6, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 4, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 4, 2024 TROA
CORRECTION SENT TO IB
Nov 27, 2023 CRSN
CORRECTION CREATED FOR IB
Nov 27, 2023 CRCR
REFUSAL PROCESSED BY IB
Oct 31, 2023 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Oct 5, 2023 RFCS
REFUSAL PROCESSED BY MPU
Oct 4, 2023 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 24, 2023 RFCR
NON-FINAL ACTION WRITTEN
Sep 23, 2023 CNRT
ASSIGNED TO EXAMINER
Sep 11, 2023 DOCK
APPLICATION FILING RECEIPT MAILED
Jan 7, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 3, 2023 NWOS
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
Dec 30, 2022 SDRC